Potent antitumor effects of nab-rapamycin (ABI-009) in combination with kinase inhibitors Erlotinib and Perifosine
Author(s): Neil Desai, Osmond D'Cruz, Vuong Trieu. Abraxis BioScience, LLC., Los Angeles, CA
Time/location: 1:00 PM - 5:00 PM, Hall B-F, Poster Section 33, # 9
Abstract Summary: According to Investigators, this study confirmed results by Cirstea et al. that dual inhibition of the Akt pathway by rapamycin (ABI-009) and Perifosine induces synergistic anti-tumor activity in multiple myeloma (AACR Annual Meeting 2008, #4181). The synergy of these combinations confirms Investigators' hypothesis that rapamycin is active only on mTORC1 and inhibition of mTORC2 by either Erlotinib or Perifosine is necessary to achieve complete shutdown of mTOR signaling pathway.
The following abstract was presented yesterday:
Evidence implicating Bim activation/induction in potentiation of PI3K/Akt inhibitor-mediated apoptosis in human leukemia cells
Author(s): Mohamed Rahmani, Anh Anderson, Joseph Reza Habibi, Timothy Ryan Crabtree, Hisashi Harada, Paul Dent, Steven Grant. VCU Massey Cancer Ctr., Richmond, VA
Abstract Summary: Investigators conclude that findings from this study suggest that Bim activation plays a key role in potentiating the antineoplastic activity of PI3K/Akt inhibitors in human leukemia cells, and raise the possibility that this phenomenon may contribute to synergistic interactions between PI3K/Akt and MEK1/2 inhibitors in such cells.
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved